Online inquiry

IVTScrip™ mRNA-Anti-IL17A, LY2439821(Cap 1, 5-Methyl-CTP, 120 nt-poly(A))   (CAT#: GTTS-WQ10424MR)

This product GTTS-WQ10424MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets IL17A gene. The antibody can be applied in Ankylosing spondylitis (AS) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 1
Species Humanized
RefSeq NM_002190.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3605
UniProt ID Q16552
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IL17A, LY2439821(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) (GTTS-WQ10424MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ13705MR IVTScrip™ mRNA-Anti-ERBB2, RC48(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA RC48
GTTS-WQ11668MR IVTScrip™ mRNA-Anti-HA, MHAA4549A(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA MHAA4549A
GTTS-WQ14798MR IVTScrip™ mRNA-Anti-CD70, SGN-70(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA SGN-70
GTTS-WQ6543MR IVTScrip™ mRNA-Anti-TNF, D2E7(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA D2E7
GTTS-WQ4593MR IVTScrip™ mRNA-Anti-CD40LG, BMS-986004(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA BMS-986004
GTTS-WQ14760MR IVTScrip™ mRNA-Anti-TNFRSF8, SGN-35(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA SGN-35
GTTS-WQ5462MR IVTScrip™ mRNA-Anti-tcdB, CDB-1(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA CDB-1
GTTS-WQ1807MR IVTScrip™ mRNA-Anti-CD19, ADCT-402(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA ADCT-402
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW